258 related articles for article (PubMed ID: 33540821)
41. Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential?
Prado CM; Sawyer MB; Ghosh S; Lieffers JR; Esfandiari N; Antoun S; Baracos VE
Am J Clin Nutr; 2013 Oct; 98(4):1012-9. PubMed ID: 23966429
[TBL] [Abstract][Full Text] [Related]
42. Skeletal muscle function during the progression of cancer cachexia in the male Apc
VanderVeen BN; Hardee JP; Fix DK; Carson JA
J Appl Physiol (1985); 2018 Mar; 124(3):684-695. PubMed ID: 29122966
[TBL] [Abstract][Full Text] [Related]
43. Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia.
Shukla SK; Markov SD; Attri KS; Vernucci E; King RJ; Dasgupta A; Grandgenett PM; Hollingsworth MA; Singh PK; Yu F; Mehla K
Cancer Lett; 2020 Aug; 484():29-39. PubMed ID: 32344015
[TBL] [Abstract][Full Text] [Related]
44. Cachexia does not induce loss of myonuclei or muscle fibres during xenografted prostate cancer in mice.
Winje IM; Sheng X; Hansson KA; Solbrå A; Tennøe S; Saatcioglu F; Bruusgaard JC; Gundersen K
Acta Physiol (Oxf); 2019 Mar; 225(3):e13204. PubMed ID: 30325108
[TBL] [Abstract][Full Text] [Related]
45. Preclinical Models for Studying the Impact of Macrophages on Cancer Cachexia.
Markov SD; Gonzalez D; Mehla K
Curr Protoc Pharmacol; 2020 Dec; 91(1):e80. PubMed ID: 33264501
[TBL] [Abstract][Full Text] [Related]
46. Aerobic and resistance training dependent skeletal muscle plasticity in the colon-26 murine model of cancer cachexia.
Khamoui AV; Park BS; Kim DH; Yeh MC; Oh SL; Elam ML; Jo E; Arjmandi BH; Salazar G; Grant SC; Contreras RJ; Lee WJ; Kim JS
Metabolism; 2016 May; 65(5):685-698. PubMed ID: 27085776
[TBL] [Abstract][Full Text] [Related]
47. Ghrelin relieves cancer cachexia associated with the development of lung adenocarcinoma in mice.
Tsubouchi H; Yanagi S; Miura A; Matsumoto N; Kangawa K; Nakazato M
Eur J Pharmacol; 2014 Nov; 743():1-10. PubMed ID: 25257464
[TBL] [Abstract][Full Text] [Related]
48. Metabolic derangements of skeletal muscle from a murine model of glioma cachexia.
Cui P; Shao W; Huang C; Wu CJ; Jiang B; Lin D
Skelet Muscle; 2019 Jan; 9(1):3. PubMed ID: 30635036
[TBL] [Abstract][Full Text] [Related]
49. Impaired Muscle Regeneration in Cancer-Associated Cachexia.
Arneson PC; Doles JD
Trends Cancer; 2019 Oct; 5(10):579-582. PubMed ID: 31706505
[TBL] [Abstract][Full Text] [Related]
50. Increased hypoxia-inducible factor-1α in striated muscle of tumor-bearing mice.
Devine RD; Bicer S; Reiser PJ; Wold LE
Am J Physiol Heart Circ Physiol; 2017 Jun; 312(6):H1154-H1162. PubMed ID: 28341633
[TBL] [Abstract][Full Text] [Related]
51. Tumor inoculation site affects the development of cancer cachexia and muscle wasting.
Matsuyama T; Ishikawa T; Okayama T; Oka K; Adachi S; Mizushima K; Kimura R; Okajima M; Sakai H; Sakamoto N; Katada K; Kamada K; Uchiyama K; Handa O; Takagi T; Kokura S; Naito Y; Itoh Y
Int J Cancer; 2015 Dec; 137(11):2558-65. PubMed ID: 26016447
[TBL] [Abstract][Full Text] [Related]
52. Effects of the PPARgamma agonist GW1929 on muscle wasting in tumour-bearing mice.
Moore-Carrasco R; Figueras M; Ametller E; López-Soriano FJ; Argilés JM; Busquets S
Oncol Rep; 2008 Jan; 19(1):253-6. PubMed ID: 18097603
[TBL] [Abstract][Full Text] [Related]
53. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
[TBL] [Abstract][Full Text] [Related]
54. Mass-dependent decline of skeletal muscle function in cancer cachexia.
Gorselink M; Vaessen SF; van der Flier LG; Leenders I; Kegler D; Caldenhoven E; van der Beek E; van Helvoort A
Muscle Nerve; 2006 May; 33(5):691-3. PubMed ID: 16372346
[TBL] [Abstract][Full Text] [Related]
55. Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia.
Ham DJ; Murphy KT; Chee A; Lynch GS; Koopman R
Clin Nutr; 2014 Jun; 33(3):448-58. PubMed ID: 23835111
[TBL] [Abstract][Full Text] [Related]
56. Development of metabolic and contractile alterations in development of cancer cachexia in female tumor-bearing mice.
Lim S; Deaver JW; Rosa-Caldwell ME; Haynie WS; Morena da Silva F; Cabrera AR; Schrems ER; Saling LW; Jansen LT; Dunlap KR; Wiggs MP; Washington TA; Greene NP
J Appl Physiol (1985); 2022 Jan; 132(1):58-72. PubMed ID: 34762526
[TBL] [Abstract][Full Text] [Related]
57. Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia.
Martinelli GB; Olivari D; Re Cecconi AD; Talamini L; Ottoboni L; Lecker SH; Stretch C; Baracos VE; Bathe OF; Resovi A; Giavazzi R; Cervo L; Piccirillo R
Oncogene; 2016 Dec; 35(48):6212-6222. PubMed ID: 27212031
[TBL] [Abstract][Full Text] [Related]
58. C/EBPβ promotes the expression of atrophy-inducing factors by tumours and is a central regulator of cancer cachexia.
AlSudais H; Rajgara R; Saleh A; Wiper-Bergeron N
J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):743-757. PubMed ID: 35014202
[TBL] [Abstract][Full Text] [Related]
59. The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia.
Bonetto A; Rupert JE; Barreto R; Zimmers TA
J Vis Exp; 2016 Nov; (117):. PubMed ID: 27929469
[TBL] [Abstract][Full Text] [Related]
60. Reduced sucrose nonfermenting AMPK-related kinase (SNARK) activity aggravates cancer-induced skeletal muscle wasting.
Alves CRR; MacDonald TL; Nigro P; Pathak P; Hirshman MF; Goodyear LJ; Lessard SJ
Biomed Pharmacother; 2019 Sep; 117():109197. PubMed ID: 31387190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
